eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2020
vol. 16
 
Share:
Share:
more
 
 
Image in intervention

Transseptal mitral valve-in-valve implantation helps to elucidate the degree of concomitant aortic valve stenosis

Jerzy Sacha
1, 2
,
Krzysztof Krawczyk
1
,
Paweł Tomaszewski
3
,
Jarosław Bugajski
1
,
Radosław Gawroński
3
,
Davide Gabbieri
4

1.
Department of Cardiology, University Hospital in Opole, Opole, Poland
2.
Faculty of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland
3.
Department of Cardiac Surgery, University Hospital in Opole, Opole, Poland
4.
Department of Cardiovascular Surgery, Hesperia Hospital, Modena, Italy
Adv Interv Cardiol 2020; 16, 4 (62): 516–518
Online publish date: 2021/01/05
Article file
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 
Evaluation of the severity of aortic valve stenosis (AVS) in concomitant significant mitral valve regurgitation is challenging. Since the risk of double-valve versus single-valve surgery is remarkably higher, reliable assessment of multivalvular heart disease is crucial, particularly in the case of re-operation [1]. This clinical example demonstrates how a transseptal mitral valve-in-valve implantation may help to elucidate the degree of borderline AVS. In addition, the double wire technique of the valve implantation is presented. A 77-year-old woman after biological valve implantation in 2006 (Hancock II 29 mm) was admitted due to heart failure symptoms (NYHA III). She also suffered from chronic atrial fibrillation, hypertension, hypercholesterolemia, coxarthrosis and spondylarthrosis, and she experienced a brain stem stroke in 2013. Transthoracic and transesophageal echocardiography revealed good left ventricular function (ejection fraction 57%), severe mitral prothesis regurgitation due to leaflet perforation (Figure 1 A) (ERO 0.51 cm2, regurgitation volume 80 ml, maximal/mean gradient 21/6 mm Hg), moderate functional tricuspid valve regurgitation and borderline AVS (aortic valve area (AVA) calculated from the continuity equation 1.1 cm2 and its index (AVAI) 0.67 cm2/m2; on planimetry, AVA 0.98 cm2, AVAI 0.59 cm2/m2; maximal/mean gradient 28/14 mm Hg). Since the stroke volume and its index were borderline (SV 60 ml, SVI 36 ml/m2, respectively) and the mitral regurgitation volume was high, the severity of AVS could not be determined – i.e., it was possible that after fixing the mitral regurgitation the aortic stenosis would become significant, particularly as the calcium score according to multi-slice computed tomography (MSCT) was high (i.e. 1555) [1]. According to EuroSCORE II and STS, the risk of surgical mortality for mitral valve re-operation was 12.21% and 7.6% respectively; however, the risk of a double valve operation was certainly much higher but undetermined. After interdisciplinary discussion, the Heart Team recommended a transcatheter mitral valve-in-valve implantation, then an intra-operative assessment of the aortic valve and a transcatheter aortic valve implantation (TAVI) in the case of significant aortic stenosis. On MSCT, the risk of significant left ventricular outflow tract (LVOT) obstruction was low (the estimated neo-LVOT area was 2.3 cm2). Using a transseptal approach, a 29-mm SAPIEN3 (Edwards Lifesciences) transcatheter valve was implanted with a double wire technique (Figures 1 B–E). In this technique, two small Safari wires (Boston Scientific) are inserted through an interatrial septum and mitral bio-prothesis into the left ventricle. One of the wires serves as a buddy wire and facilitates SAPIEN3 valve delivery – such a wire is helpful if the SAPIEN3 valve is stuck at the septum or at the annulus of the bio-prothesis since it enables a small balloon to be inserted and the valve to be pushed in the right direction [2]. After successful implantation, the invasive and non-invasive evaluation revealed a moderate degree of AVS (AVA 1.1 cm2, maximal/mean gradient 24/11 mm Hg), and hence, TAVI was abandoned. During 6-month follow-up, the patient was asymptomatic with good function of the implanted SAPIEN3 valve and no signs of progression of aortic stenosis. This case shows that a transcatheter approach may help to manage multivalvular heart disease in an evidence-based manner.

Conflict of interest

The authors declare no conflict of interest.

References

1. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38: 2739-91.
2. Hachinohe D, Latib A, Mitomo S, et al. Usefulness of buddy wire technique during transcatheter transseptal mitral valve implantation in degenerated mitral bioprosthesis. Circ J 2018; 83: 243-4.
Copyright: © 2021 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe